Nutex Health

NUTX

Market cap $721M

New York, New York--(Newsfile Corp. - March 5, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nutex Health, Inc. (NASDAQ: NUTX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Nutex Health caused the company to misrepresent or fail to disclose that: (i) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iv) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (v) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (vi) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the SEC; (vii) accordingly, Nutex's business and/or financial prospects were overstated; and (viii) as a result, public statements were materially false and misleading at all relevant times.

Nutex Health is rated a buy, driven by the potential passage of the No Surprises Enforcement Act. NUTX's $387 million in receivables could rapidly convert to cash if the bill passes, eliminating a key valuation overhang. The company trades at 5.2x P/E despite 49% projected 2026 revenue growth and a 27% TTM operating margin, reflecting market skepticism over payment collections.

HOUSTON, Feb. 25, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, on Thursday, March 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day.

HOUSTON, Jan. 12, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 27 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced the reopening of Bayou City ER & Hospital, located northeast of Houston at 19211 McKay Dr., Humble, Texas. The staff of medical experts at Bayou City ER & Hospital are bringing the community 24/7/365 days of concierge-level care.

HOUSTON, Jan. 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 26 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that the Company's CEO, Dr. Tom Vo, CFO, Mr. Jon Bates, and President, Dr. Warren Hosseinion will attend and present at the 2026 J.P.

A gold stock and a hospital name were the top two 2025 performers on a list of growth stocks. Both may still have room to run.

HOUSTON , Dec. 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 26 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced the opening of its 26th hospital in a new state: Missouri. Archview ER & Hospital is located at 1320 N.

LOS ANGELES , Dec. 11, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nutex Health Inc. ("Nutex" or "the Company") (NASDAQ: NUTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

HOUSTON , Dec. 4, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 25 state-of-the-art micro hospitals and hospital outpatient departments in 11 states and primary care-centric, risk-bearing physician networks, today announced that its Board of Directors has approved an extension of the previously authorized stock repurchase program. The program, originally announced on August 14, 2025, authorized the repurchase of up to $25.0 million of the Company's common stock over a six-month period, commencing upon the filing of the Company's Form 10-Q for the quarter ended June 30, 2025.

Nutex Health Inc. (NUTX) Discusses Restated 2024 Results and Combined Second and Third Quarter 2025 Financial Performance Transcript